Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy

  • participants needed
  • sponsor
    University Hospital Tuebingen
Updated on 22 January 2022


to show that 1. patients improve and stabilize after 12 -24 week treatment with rivastigmine in memory function 2. use of rivastigmine has a positive effect on apathy in PSP patients 3. therapy with rivastigmine has a no positive benefit on speech and overall results of the MMST 4. changes in motor activity are associated with changes in language and overall results of the in MMST

Condition Progressive Supranuclear Palsy, Progressive Supranuclear Palsy, Dementia, Dementia, Alzheimer's Disease, Alzheimer's Disease
Treatment rivastigmine
Clinical Study IdentifierNCT00522015
SponsorUniversity Hospital Tuebingen
Last Modified on22 January 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note